专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2016123076A1 STABLE 5-METHYLTRAHYDROFOLATE FORMULATIONS TO MODERATE METHYLENETETRAHYDROFOLATE REDUCTASE ASSOCIATED POLYMORPHISMS 审中-公开
标题翻译：稳定的5-甲基三氟甲磺酸盐配方，以改善甲基偏氟乙酸降低相关多态性
公开(公告)号：WO2016123076A1
公开(公告)日：2016-08-04
申请号：PCT/US2016/014868
申请日：2016-01-26
申请人： LA VITA COMPOUNDING PHARMACY
发明人： HUBERS, Debra, K. , GIVANT, Christine, A.
IPC分类号： C30B29/54 , C30B30/06 , C07D475/04 , A61K31/519
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/0043 , A61K9/006 , A61K9/08 , A61K31/714 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/20 , A61K47/22 , C07D475/04
摘要： Provided herein are methods for preparing stable solutions containing 5- methyltetrahydrofolate (MTHF). Also provided herein are stable compositions containing calcium 5-methyltetrahydrofolate (MTHF-Ca).
摘要翻译：本文提供了制备含有5-甲基四氢叶酸（MTHF）的稳定溶液的方法。本文还提供含有5-甲基四氢叶酸钙（MTHF-Ca）的稳定组合物。

32. 发明申请

WO2016122832A1 COMPOSITIONS, THERAPEUTIC AND PROPHYLACTIC METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND BRAIN INJURIES 审中-公开
标题翻译：用于治疗神经损伤性疾病和脑损伤的组合物，治疗和预防方法
公开(公告)号：WO2016122832A1
公开(公告)日：2016-08-04
申请号：PCT/US2016/000012
申请日：2016-01-28
申请人： NATURAL FORMULATIONS , LaVALLE, James, B.
发明人： LaVALLE, James, B.
IPC分类号： A61P25/28 , A61K31/704 , A61K9/72
CPC分类号： A61K31/704 , A61K9/0043 , A61K31/706 , A61K31/714 , A61K47/20 , A61K47/26 , A61K47/40 , A61K2300/00
摘要： Disclosed are compositions comprising Rg3 ginsenoside and nicotinamide riboside. These compositions are useful for treating and preventing diseases, conditions and disorders caused by microglia-mediated inflammation, including neurodegenerative diseases and brain injuries.
摘要翻译：公开了包含Rg3人参皂苷和烟酰胺核苷的组合物。这些组合物可用于治疗和预防由小胶质细胞介导的炎症引起的疾病，病症和病症，包括神经变性疾病和脑损伤。

33. 发明申请

WO2016118540A1 TREATING AND/OR PREVENTING EMESIS AND/OR NAUSEA INCLUDING ACUTE AND/OR DELAYED NAUSEA AND/OR EMESIS 审中-公开
标题翻译：治疗和/或预防EMESIS和/或NAUSEA，包括急性和/或延迟的NAUSEA和/或EMESIS
公开(公告)号：WO2016118540A1
公开(公告)日：2016-07-28
申请号：PCT/US2016/013979
申请日：2016-01-20
申请人： XOC PHARMACEUTICALS, INC.
发明人： ARMER, Thomas , MCKINLEY, Geoff , BORLAND, Scott , GUZMAN, Miguel
IPC分类号： A61K31/439 , A61K9/12 , A61P1/08
CPC分类号： A61K31/473 , A61K9/0043 , A61K9/0075 , A61K9/0078 , A61K9/008
摘要： Methods for treating and/or preventing nausea and emesis including acute and/or delayed nausea and/or acute and/or delayed emesis in a subject are provided herein. The methods include administering to the subject in need thereof a therapeutically effective amount of a 5HT 3 antagonist or a pharmaceutical composition thereof by nasal inhalation and/or oral inhalation.
摘要翻译：本文提供了治疗和/或预防恶心和呕吐的方法，包括受试者中急性和/或延迟的恶心和/或急性和/或延迟性呕吐。所述方法包括向有需要的受试者施用治疗有效量的5HT3拮抗剂或其药物组合物，其通过鼻吸入和/或口服吸入。

34. 发明申请

WO2016115147A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES 审中-公开
标题翻译：包含POH衍生物的药物组合物
公开(公告)号：WO2016115147A1
公开(公告)日：2016-07-21
申请号：PCT/US2016/013065
申请日：2016-01-12
申请人： NEONC TECHNOLOGIES INC.
发明人： CHEN, Thomas , LEVIN, Daniel , PUPALLI, Satish
IPC分类号： A61K47/48
CPC分类号： A61K47/481 , A61K9/0043 , A61K31/4015 , A61K31/415 , A61K45/06 , A61K47/54 , A61K47/55 , A61N5/10 , C07D207/26 , C07D231/12 , C07D487/04
摘要： The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram. The present invention provides for a pharmaceutical composition comprising a perillyl alcohol carbamate. The perillyl alcohol carbamate may be perillyl alcohol conjugated with a therapeutic agent, such as a chemotherapeutic agent. The chemotherapeutic agent may be rolipram. In one embodiment, the perillyl alcohol carbamate may 4-(3-cyclopentyloxy-4- methoxy phenyl)-2-oxo-pyrrolidine-1-carboxylic acid 4-isopropenyl cyclohex- 1 -enylmethyl ester (POH-Rolipram).
摘要翻译：本发明提供了诸如POH-Rolipram的珀素醇（POH）氨基甲酸酯。本发明还提供了通过向患者递送治疗有效量的POH-咯利普兰来治疗疾病如癌症的方法。本发明提供了一种药物组合物，其包含氨基甲酸环己烷醇酯。芳族醇氨基甲酸酯可以是与治疗剂缀合的芳香醇，例如化学治疗剂。化疗剂可以是咯利普兰。在一个实施方案中，芳族醇氨基甲酸酯可以是4-（3-环戊氧基-4-甲氧基苯基）-2-氧代 - 吡咯烷-1-甲酸4-异丙烯基环己-1-烯基甲酯（POH-Rolipram）。

35. 发明申请

WO2016112205A1 MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USE 审中-公开
标题翻译：含镁含氧化合物制剂及其使用方法
公开(公告)号：WO2016112205A1
公开(公告)日：2016-07-14
申请号：PCT/US2016/012512
申请日：2016-01-07
申请人： TRIGEMINA, INC.
发明人： YEOMANS, David, C. , CARSON, Dean , THIRUCOTE, Ramachandran
IPC分类号： A61K38/11 , A61K33/06 , C07K7/16 , A61P25/04 , A61P25/06
CPC分类号： A61K33/06 , A61K9/0043 , A61K38/11 , A61K45/06 , A61K47/02 , A61K47/12 , A61M15/08 , A61K2300/00
摘要： Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.
摘要翻译：公开了含镁催产素肽制剂或包含催产素肽和镁盐的组合物，当用于治疗疼痛时产生协同镇痛。还公开了用于治疗包括共同给予催产素肽和镁盐的疼痛（如偏头痛头痛）的方法。

36. 发明申请

WO2016081826A3 ENVENOMATION THERAPIES AND RELATED PHARMACEUTICAL COMPOSITIONS, SYSTEMS AND KITS 审中-公开
标题翻译：环境治疗和相关药物组合物，系统和试剂盒
公开(公告)号：WO2016081826A3
公开(公告)日：2016-07-14
申请号：PCT/US2015061834
申请日：2015-11-20
申请人： OPHIREX INC
发明人： LEWIN MATTHEW R
IPC分类号： A61K31/00 , A61P39/02
CPC分类号： A61K31/404 , A61K9/0019 , A61K9/0043 , A61K31/16 , A61K31/167 , A61K31/24 , A61K31/245 , A61K31/381 , A61K31/405 , A61K31/445 , A61K31/541 , A61K38/57 , A61K39/39533 , A61K45/06 , C07K16/18 , C07K2317/55 , A61K2300/00
摘要： The invention provides methods of treatment, pharmaceutical compositions, systems and kits appropriate for first line and/or adjunct therapy with antivenom using at least one active component, in some instances at least two active components and in other instances no more than two active components selected from the group consisting of a selective secretory PLA2 inhibitor (sPLA2 or PLA2 inhibitor), a metalloproteinase inhibitor, a serine protease inhibitor, antivenom, one or more acetylcholinesterase inhibitors or a nAChR agonist paired with a mAChR antagonist, a NMDA receptor antagonist and a spreading factor inhibitor to treat a subject who suffers from an envenomation, preferably at the time of envenomation and often within a period of less than about an hour after an envenomation or 6 hours after an envenomation and throughout the course of treatment at time with or without antivenom as an adjunct therapy after an envenomation by, for example, a snake or invertebrate.
摘要翻译：本发明提供了治疗方法，药物组合物，系统和试剂盒，其适用于使用至少一种活性成分（在一些情况下至少两种活性成分）和其它情况下不超过两种选择的活性成分的抗蛇毒素的一线和/或辅助治疗来自由选择性分泌型PLA2抑制剂（sPLA2或PLA2抑制剂）组成的组，金属蛋白酶抑制剂，丝氨酸蛋白酶抑制剂，抗蛇毒药，一种或多种乙酰胆碱酯酶抑制剂或与mAChR拮抗剂配对的nAChR激动剂，NMDA受体拮抗剂和扩散剂因子抑制剂治疗患有envenomation的受试者，优选在嗅觉时，并且通常在envenomation之后不到约一小时或在envenomation后6小时期间以及在有或没有antivenom的整个治疗过程中作为例如蛇或无脊椎动物进行修复后的辅助疗法。

37. 发明申请

WO2016079271A1 INTRANASAL ADMINISTRATION 审中-公开
标题翻译：行政管理
公开(公告)号：WO2016079271A1
公开(公告)日：2016-05-26
申请号：PCT/EP2015/077166
申请日：2015-11-19
申请人： OPTINOSE AS
发明人： DJUPESLAND, Per Gisle , SHELDRAKE, Colin David
IPC分类号： A61M15/08 , A61M15/00
CPC分类号： A61M15/08 , A61K9/0043 , A61K38/08 , A61K38/11 , A61M11/00 , A61M15/0013 , A61M15/0021 , A61M15/009 , A61M15/0098 , A61M29/00 , A61M31/00 , A61M2202/04 , A61M2202/064 , A61M2210/0618
摘要： A nosepiece for delivering substance to a nasal cavity of a subject, the nosepiece comprising a body part which comprises a base portion which defines a flow passage therethrough, and a projection at a distal end of the base portion which at least in part provides a tip of the nosepiece and confers a rigidity in the sagittal direction, which enables the tip to open fleshy tissue at an upper region of the nasal valve and thereby expand an open area of the nasal valve, and a flexibility in a lateral direction, orthogonal to the sagittal plane, which facilitates insertion of the tip into the nasal valve.
摘要翻译：一种用于将物质输送到受试者的鼻腔的鼻梁，鼻梁包括主体部分，其包括限定通过其的流动通道的基部，以及在基部的远端处的突起，其至少部分地提供尖端并且赋予矢状方向上的刚性，这使得尖端可以在鼻阀的上部区域打开肉质组织，从而扩大鼻阀的开放区域，并且在横向方向上的柔性在正交于鼻塞矢状面，其有助于将尖端插入到鼻阀中。

38. 发明申请

WO2016077190A1 PROBIOTIC THERAPEUTIC APPLICATIONS 审中-公开
标题翻译： PROBIOTIC THERAPEUTIC应用
公开(公告)号：WO2016077190A1
公开(公告)日：2016-05-19
申请号：PCT/US2015/059662
申请日：2015-11-09
申请人： NATIONAL INSTITUTES OF HEALTH , GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
发明人： WILFRET, David, A. , KEICHER, Jesse, Daniel , ROSENBERG, Helene, Fischer
IPC分类号： A61K35/74 , A61P11/00
CPC分类号： A61K35/747 , A61K9/0043 , A61K9/0075 , A61K9/1617 , A61K9/1623 , A61M15/00 , A61M2202/064 , Y02A50/491
摘要： Aspects of the present invention are related to the use of Lactobacillus species in a composition for respiratory administration to prevent the pathogenic inflammatory sequelae of respiratory virus infections.
摘要翻译：本发明的方面涉及在用于呼吸施用的组合物中使用乳杆菌属物种以预防呼吸道病毒感染的致病性炎性后遗症。

39. 发明申请

WO2016072939A1 FORMULATIONS COMPRISING ANTIMICROBIAL AGENTS WITH HYDROPHOBIC MOIETIES AND USES THEREOF 审中-公开
标题翻译：包含具有疏水性动物的抗微生物剂的制剂及其用途
公开(公告)号：WO2016072939A1
公开(公告)日：2016-05-12
申请号：PCT/SG2015/050435
申请日：2015-11-05
申请人： NATIONAL UNIVERSITY OF SINGAPORE , NATIONAL UNIVERSITY HOSPITAL(S) PTE LTD
发明人： HO, Chi Lui Paul , TEO, Chun Hwee Desmond , TEO, Woon Pei Jeanette , PEE, Hai Ning
IPC分类号： A61K31/724 , A61K31/055 , A61K31/44 , A61K31/351 , A61K31/755 , A61K31/155 , A61P31/00 , A61P33/00
CPC分类号： A61K31/351 , A61K9/0043 , A61K31/085 , A61K31/444 , A61K47/38 , A61K47/40 , Y02A50/473
摘要： The present disclosure discusses formulations comprising hydrophobic antimicrobial agents and uses thereof. More precisely, the present disclosure refers to a composition comprising a hydrophobic antimicrobial agent and a cyclodextrin.
摘要翻译：本公开内容讨论了包含疏水性抗微生物剂及其用途的制剂。更准确地说，本发明涉及包含疏水性抗微生物剂和环糊精的组合物。

40. 发明申请

WO2016065282A1 NASAL FORMULATION, NASAL KIT, AND METHOD FOR ENHANCING NASAL NITRIC OXIDE (NO) LEVELS 审中-公开
标题翻译： NASAL制剂，NASAL工具包和用于增强NASAL NITRIC OXIDE（NO）水平的方法
公开(公告)号：WO2016065282A1
公开(公告)日：2016-04-28
申请号：PCT/US2015/057154
申请日：2015-10-23
申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN
发明人： MEYERHOFF, Mark, E. , JENSEN, Gary, C. , BALIJEPALLI, Anant , SAJJAN, Umadeyi , ZACHAREK, Mark , HERSHENSON, Marc
IPC分类号： A61K9/12 , A61K9/14 , A61K38/17
CPC分类号： A61K47/02 , A61K9/0043 , A61K31/198 , A61K31/40 , A61K31/445 , A61K38/10 , A61K38/1706 , A61K2300/00
摘要： A nasal formulation includes a liquid carrier to be introduced into upper airways through a nasal cavity. Present in the liquid carrier are low molecular weight arginine-rich peptides derived from protamine. When introduced into the upper airways, the low molecular weight arginine-rich peptides are to increase nitric oxide (NO) levels in the upper airways. The nasal formulation has a pH ranging from 4 to 10.
摘要翻译：鼻制剂包括通过鼻腔引入上呼吸道的液体载体。存在于液体载体中的是由鱼精蛋白衍生的低分子量富含精氨酸的肽。当引入上呼吸道时，低分子量富含精氨酸的肽会增加上呼吸道中的一氧化氮（NO）水平。鼻制剂的pH范围为4至10。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式